Swiss come onboard, but shunned EU GMP ‘standard’ may bring drug shortages
This article was originally published in Scrip
As Switzerland becomes the first country to receive an "equivalence" rating from the European Commission for its regulations on active pharmaceutical ingredients (APIs), many of the biggest API manufacturing countries including India and China have still not even applied for an equivalence assessment.
You may also be interested in...
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.
The team behind Russia’s first COVID-19 vaccine has asked for scientific advice from EU drug regulators in view of a possible submission for marketing authorization.